Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Aldeyra Therapeutics, Inc. clinical trials
Also known as Aldexa Therapeutics.
The registry lists 35 studies whose lead sponsor is Aldeyra Therapeutics, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 3, 2026.
Keep track of what changes. Save the Aldeyra Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Aldeyra Therapeutics, Inc..
- Aldeyra Therapeutics, Inc.35 studiesSame company
Something wrong?
Focus areas
Conditions Aldeyra Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 35 of 35.
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaRecruitingNCT07402876Phase 3
- A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)CompletedNCT06685692Phase 2
- The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic ConjunctivitisCompletedNCT05234554Phase 3
- A Study in Subjects With Retinitis PigmentosaCompletedNCT05392179Phase 2
- A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseCompletedNCT06493604Phase 3
- A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedNCT04735393Phase 3
- A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseCompletedNCT06424444Phase 3
- The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyCompletedNCT04136366Phase 3
- A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye DiseaseCompletedNCT06389214Phase 3
- A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic ConjunctivitisCompletedNCT03660878Phase 1/2
- The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseCompletedNCT04674358Phase 2/3
- The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseCompletedNCT05062330Phase 3
- A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisCompletedNCT04908514Phase 2
- A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseaseCompletedNCT03916042Phase 2
- A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic CoughCompletedNCT05392192Phase 2
- A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol LevelsCompletedNCT05487404Phase 1/2
- An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease ChamberCompletedNCT05102409Phase 2
- A Clinical Trial to Assess Subjects With Dry Eye Disease.CompletedNCT04971031Phase 2
- A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure ChamberCompletedNCT03709121Phase 1/2
- A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.CompletedNCT04847544Phase 2
- A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)CompletedNCT04728711Phase 2
- ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic ConjunctivitisCompletedNCT03494504Phase 3
- SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.CompletedNCT03131154Phase 3
- A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseCompletedNCT03404115Phase 2
- The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseCompletedNCT03879863Phase 3
- A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye SyndromeCompletedNCT03162783Phase 2
- A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye DiseaseCompletedNCT05424549Phase 2
- The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.CompletedNCT04207736Phase 3
- A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)CompletedNCT05717920Phase 2
- Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic SyndromeWithdrawnNCT05599815Phase 2
- A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisCompletedNCT02578914Phase 2
- A Safety and Efficacy Study of NS2 in Patients With Anterior UveitisCompletedNCT02406209Phase 2
- RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)CompletedNCT03445650Phase 3
- A Study of ADX-102 in Subjects With Allergic ConjunctivitisCompletedNCT03012165Phase 2
- A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)CompletedNCT02402309Phase 2